Get started
Author

Gill Coombes

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
2011 · Tom Treasure, Loic Lang-Lazdunski, et al. · The Lancet Oncology · 708
Excision Margins in High-Risk Malignant Melanoma
2004 · J. Meirion Thomas, Julia Newton-Bishop, et al. · New England Journal of Medicine · 503
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
2013 · Stephen RD Johnston, Lucy S Kilburn, et al. · The Lancet Oncology · 274
PDF
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
1996 · R C Coombes, J M Bliss, et al. · Journal of Clinical Oncology · 170
Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group
1999 · J.A. Wils, J.M. Bliss, et al. · Journal of Clinical Oncology · 79
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in theneo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
2004 · I.E. Smith, R.P. A’Hern, et al. · Annals of Oncology · 60
PDF
A Quality-of-Life Study in High-Risk (Thickness≥2 mm) Cutaneous Melanoma Patients in a Randomized Trial of 1-cm versus 3-cm Surgical Excision Margins
2004 · Julia A. Newton-Bishop, Clarissa Nolan, et al. · Journal of Investigative Dermatology Symposium Proceedings · 47
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)
2005 · S. Chua, I.E. Smith, et al. · Annals of Oncology · 40
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2014 · Alexandra Leary, Abigail Evans, et al. · Clinical Cancer Research · 30
2LBA Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor – First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747)
2012 · S. Johnston, L.S. Kilburn, et al. · European Journal of Cancer · 21
Combining Fulvestrant (Faslodex™) with Continued Oestrogen Suppression in Endocrine-sensitive Advanced Breast Cancer: the SoFEA Trial
2008 · D. Dodwell, G. Coombes, et al. · Clinical Oncology · 20
A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial
2010 · B. Sirohi, R. A'Hern, et al. · Annals of Oncology · 9
PDF
The MARS feasibility trial: conclusions not supported by data reply
2011 · Bliss, J.M., Coombes, G., et al. · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) · 6
59 The mesothelioma and radical surgery (MARS) trial update
2007 · N. Duffy, C. Peckitt, et al. · Lung Cancer · 3
182 The Mesothelioma and Radical Surgery (MARS) trial update
2006 · T. Treasure, N. Duffy, et al. · Lung Cancer · 3
Abstract PD07-07: Prediction of antiproliferative response to lapatinib by HER3 in an exploratory analysis of HER2-non-amplified (HER2−) breast cancer in the MAPLE presurgical study (CRUK E/06/039)
2012 · M Dowsett, A Leary, et al. · Cancer Research · 2
53 Principal results of the feasibility phase of the Mesothelioma and Radical Surgery trial (MARS-feasibility)
2011 · T. Treasure, J.M. Bliss, et al. · Lung Cancer · 2
Abstract LB-222: Lapatinib has antiproliferative effects in both HER2 positive (+) and HER2 negative (-) breast cancer (BC): results from the MAPLE short-term pre-surgical trial (CRUK E/06/039)
2012 · Abigail Evans, Alexandra F. Leary, et al. · Cancer Research · 1
A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM).
2011 · J. M. G. Larkin, S. Turajlic, et al. · Journal of Clinical Oncology · 1
Supplementary Table and Figure Legends from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023 · Alexandra Leary, Abigail Evans, et al.
Supplementary Figure 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023 · Alexandra Leary, Abigail Evans, et al.
Supplementary Table 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023 · Alexandra Leary, Abigail Evans, et al.
Supplementary Table 4 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023 · Alexandra Leary, Abigail Evans, et al.
Supplementary Table 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023 · Alexandra Leary, Abigail Evans, et al.
Supplementary Figure 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023 · Alexandra Leary, Abigail Evans, et al.
Works count: 41
Citation count: 1,979
H-index: 11
I10-index: 11
Year
Topic
Type